Article

ARVO images

images

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
Related Content
PolyActiva secures $40 million AUD in Series C funding
June 14th 2025

PolyActiva secures $40 million AUD in Series C funding

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

EssilorLuxottica set to acquire Optegra clinics
June 13th 2025

EssilorLuxottica set to acquire Optegra clinics

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

HIV drug lamivudine shows promise in treating diabetic macular edema
June 12th 2025

HIV drug lamivudine shows promise in treating diabetic macular edema

Formosa Pharmaceuticals grants Harrow US commercial rights to clobetasol propionate ophthalmic suspension 0.05% (BYQLOVI), terminates deal with Eyenovia
June 12th 2025

Formosa Pharmaceuticals grants Harrow US commercial rights to clobetasol propionate ophthalmic suspension 0.05% (BYQLOVI), terminates deal with Eyenovia

© 2025 MJH Life Sciences

All rights reserved.